Biocon Biologics to Expand Biosimilar Oncology Portfolio, Outline Strategic Vision at the 2026 J.P. Morgan Healthcare Conference

Core Insights - Biocon Biologics Ltd. is set to introduce three new oncology biosimilars at the 2026 J.P. Morgan Healthcare Conference, enhancing its cancer portfolio and expanding access to affordable medicines [1][2][4] Oncology Portfolio - The new biosimilars include Trastuzumab/Hyaluronidase (Herceptin® SC/Herceptin HYLECTA™), Nivolumab (Opdivo®), and Pembrolizumab (Keytruda®), which will strengthen Biocon's oncology offerings [2] - Global sales for Keytruda were $29.5 billion in 2024, Opdivo sales were $9.3 billion, and combined sales for Herceptin SC and Herceptin HYLECTA were $1.72 billion in 2024 [2] - These assets are among the largest oncology biologics losing exclusivity in the next five years, joining an existing portfolio of 17 oncology medications, representing a market opportunity exceeding $75 billion [2] Corporate Integration - Biocon Limited plans to integrate Biocon Biologics as a wholly owned subsidiary, expected to be completed by March 31, 2026, to leverage global commercial infrastructure and simplify corporate structure [3] - This integration will position Biocon as a leader in diabetes, oncology, and immunology, which together account for nearly 40% of global pharmaceutical revenues [3] - The integration aims to enhance the delivery of innovative, affordable medicines to over 6 million patients across more than 120 markets [3] Leadership and Future Plans - Shreehas Tambe, CEO & Managing Director of Biocon Biologics, will present at the J.P. Morgan Healthcare Conference, discussing the integration's impact on delivering biosimilars and generics [4] - The company emphasizes a science-led R&D approach, advancing a strong pipeline of 17 oncology assets to meet diverse patient needs [4] Company Overview - Biocon Biologics is a fully integrated global biosimilars company, committed to transforming healthcare by providing affordable access to high-quality biosimilars [5][7] - The company has commercialized 10 biosimilars and has a pipeline of 20 biosimilar assets across various therapeutic areas, including oncology and diabetes [7] - Biocon Limited, publicly listed since 2004, focuses on enhancing access to complex therapies for chronic conditions like diabetes and cancer [8]